10/21/2024
At Rekom Biotech, we have always believed in growth through innovation, and now, we are thrilled to announce a major milestone in our journey. Founded in 2010 and starting the activity in 2011, we have been steadily growing, and it is time to take the next step. In the not too distant future, we will be moving into our very own building, with a Level 2 Biosecurity laboratory. We have already completed the project design and are currently in the process of obtaining all the necessary licenses.
This new facility will open exciting doors for us. It will allow us to expand our research and production capabilities by working with new expression systems, such as insect cells and mammalian cells. Therefore, this move also positions us to introduce new product lines, including the development and production of monoclonal antibodies. Additionally, we will be able to expand into new markets, such as autoimmune diseases and cancer, all of which are key focus areas for our future growth.
(...)
7/12/2024
We are pleased to announce that on July 12th, 2024, Rekom Biotech signed a new distribution agreement with Yarewell, a prominent company in the diagnostics sector in China. This agreement will allow us to expand our presence in the Chinese market, ensuring that our innovative products reach more healthcare professionals and diagnostic laboratories.
(...)
8/2/2022
Rekom Biotech is delighted to announce that we have just started a new distribution partnership with Afirmus Biosource. From now on, our customers from Singapore and Indonesia will be able to purchase our IVD raw materials with the assistance of our new partner.
(...)
7/27/2022
Rekom Biotech is pleased to announce that we have just started a new distribution partnership with Filgen Inc. From now on, our Japanese customers will be able to purchase our IVD raw materials through our new partner.
(...)
6/1/2022
We keep growing! Rekom Biotech is pleased to announce that we have just started a new distribution partnership with MoreBio Co., Ltd. From now on, MoreBio will be the responsible company supervising the distribution of our IVD reagents in the Republic of Korea.
(...)
